CommercialCoverageMedium impact
Amtagvi (lifileucel)
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology·Medical Policy
Effective date
Jan 20, 2025
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has added a new policy stating that Amtagvi (lifileucel), a tumor-derived T cell immunotherapy for metastatic melanoma, is considered NOT medically necessary because other covered treatment options exist with equivalent evidence levels. Claims for Amtagvi and its administration services will be denied.
Action Required
Immediately: Billing team must update systems to flag Amtagvi (lifileucel) as non-covered for BCBS Mississippi members with unresectable or metastatic melanoma. Providers should be notified that this drug and its administration services will be denied as not medically necessary. Update prior authorization systems to reflect coverage denial for this indication.